Brief: BioArctic Says Eisai Presented New Leqembi Data
13/07/2026 06:39
BRIEF-BioArctic Says Eisai Presented New Leqembi Data July 13 (Reuters) - BioArctic AB (publ) BIOAb.ST:
SAID ON SUNDAY PARTNER EISAI PRESENTED NEW CLINICAL DATA ON LEQEMBI SUBCUTANEOUS AUTOINJECTOR
DATA SHOW LEQEMBI (LECANEMAB) SUBCUTANEOUS AUTOINJECTOR (SC-AI) FORMULATION OFFERS EFFICACY AND SAFETY COMPARABLE TO INTRAVENOUS (IV) ADMINISTRATION IN PEOPLE WITH EARLY ALZHEIMER'S DISEASE
EFFICACY DRIVEN BY EXPOSURE, NOT ROUTE OF ADMINISTRATION
Source text for Workspace: nWkr5pbdHM
Further company coverage: [BIOAb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln